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E-mail address: hhlin@mail.cgu.edu.tw (H.-H. Lin)Auto-proteolysis at the G protein-coupled receptor (GPCR) proteolytic site (GPS) is a hallmark of
adhesion-GPCRs. Although defects in GPS auto-proteolysis have been linked to genetic disorders,
information on its regulation remains elusive. Here, we investigated the GPS proteolysis of CD97,
a human leukocyte-restricted and tumor-associated adhesion-GPCR. We found that CD97 is incom-
pletely processed, unlike its close homolog, epidermal growth factor-like module-containing
mucin-like hormone receptor 2. A unique pattern of N-glycosylation within the GPS motif of related
adhesion-GPCRs was identiﬁed. The use of N-glycosylation inhibitors and mutants conﬁrm site-spe-
ciﬁc N-glycosylation is an important determinant of GPS proteolysis in CD97. Our results suggest
that N-glycosylation may regulate the processing of adhesion-GPCRs leading to the production of
either cleaved or uncleaved molecules.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Post-translational modiﬁcation by proteolytic cleavage has
been recognized as an important mechanism for the functional
modulation of a diverse array of cell surface proteins, such as
Notch, protease-activated receptors (PARs) and many cell adhesion
molecules [1–3]. Proteolytic modiﬁcation of these molecules usu-
ally takes place in the secretory pathway or on the cell surface,
mediated by proprotein convertases or sheddases such as furin,
MMPs and ADAMs [4].
In addition to protease-mediated modiﬁcations, protease-inde-
pendent processing catalyzed by intramolecular cleavage (auto-
proteolysis) has recently gained attention as an alternative mech-
anism for receptor activation. Examples of these auto-proteolytic
modiﬁcations include the SEA module-mediated cleavage of
Muc-1 and dystroglycan [5–7], and the G protein-coupled receptor
proteolytic site (GPS) domain-mediated cleavage of adhesion-G
protein-coupled receptors (GPCRs) [8,9].chemical Societies. Published by E
, degree of cleavage; ECD,
tor module-containing seven-
actor-like module-containing
ble; GPCR, G protein-coupled
ctivated receptors; WT, wild-
.Based upon the GRAFS phylogenetic classiﬁcation system pro-
posed by Fredriksson et al., the 33 adhesion-GPCR molecules con-
stitute the second largest GPCR sub-family in the human proteome
[10]. The most distinct feature of adhesion-GPCRs is the chimeric
composition of a long extracellular domain (ECD) and the seven-
span transmembrane (7TM) region [9,11]. Unusually large among
GPCRs, the ECD of adhesion-GPCRs typically consists of multiple
protein modules, a stalk region and a novel Cys-rich GPS domain.
Speciﬁcally, the N-terminus often contains common protein motifs
known to be involved in protein–protein interactions, while the
stalk region is rich in potential N- and O-glycosylation residues.
The heavily glycosylated receptor was then dissected at the GPS
domain into extracellular a-subunit and 7TM b-subunit, which
were then expressed on the membrane as a non-covalent hetero-
dimer [9,11].
Our previous experiments on epidermal growth factor-like
module-containing mucin-like hormone receptor 2 (EMR2), an epi-
dermal growth factor module-containing seven-transmembrane
receptor (EGF-TM7) member of adhesion-GPCR family, have shown
that the GPS proteolysis is mediated by a self-catalytic reaction
similar to that of N-terminal nucleophile hydrolases [8]. We found
that the GPS cleavage, which occurs in the endoplasmic reticulum
(ER), is critically dependent on the intact stalk region and is
achieved via an intramolecular reaction involving the generation
and subsequent hydrolysis of a (thio)ester intermediate [8,12]. Ear-
lier studies have suggested that proper cleavage at GPS might be alsevier B.V. All rights reserved.
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More recently, deﬁciency in GPS cleavage has been linked to hu-
man genetic disorders. As such, point mutations affecting the
GPS cleavage of GPR56 and polycystin-1 have been implicated as
the causes of bilateral frontoparietal polymicrogyria (BFPP) and
autosomal dominant polycystic kidney disease (ADPKD), respec-
tively [14,15]. Therefore, GPS cleavage appears to be an inherent
and essential post-translational modiﬁcation for the expression,
presentation and function of adhesion-GPCRs.
Despite the direct link to diseases, little is known about the reg-
ulation of the novel self-catalytic GPS proteolytic reaction. In this
report, the GPS auto-proteolysis of CD97 was investigated. CD97
is a leukocyte-restricted and tumor-associated EGF-TM7 molecule
highly homologous to EMR2 [16,17]. The two molecules shared al-
most identical EGF-like domains and 50% homology in the stalk
and the 7TM regions. As well as functional roles in leukocyte
migration, recruitment and activation [18–21], CD97 is known to
be involved in angiogenesis and the migration and invasion of tu-
mor cells [22–24]. By analyzing the GPS cleavage of CD97-mFc-fu-
sion protein, we show herein that CD97 and EMR2 have very
different GPS cleavage efﬁciencies. Site-speciﬁc N-glycosylation
in the stalk was found to play a critical role in regulating GPS
auto-proteolysis of CD97. Our results suggest the adhesion-GPCRs
might adopt two different conformations, leading to the produc-
tion of either cleaved or uncleaved molecules.2. Materials and methods
2.1. Reagents and cell culture
General chemicals were of analytical grade and obtained from
Sigma (Dorset, UK), unless otherwise stated. CLB/CD97-1 mAb
(mouse IgG2a) and EMR2-speciﬁc 2A1 mAb (mouse IgG1) were
purchased from AbD Serotec (Kidlington, UK). Horseradish peroxi-
dase (HRP)-conjugated 2nd Ab was purchased from Sigma. All cul-
ture media were from Invitrogen (Carlsbad, CA) and were
supplemented with 10% heat inactivated fetal calf serum (FCS),
2 mM L-glutamine, 50 IU/ml penicillin and 50 lg/ml streptomycin.
HEK-293T and COS-7 were cultured in Dulbecco’s Modiﬁed Eagle
Medium (DMEM). CHO-K1 cells were grown in Ham’s F-12 med-
ium. Lec1 cells were maintained in a-minimum essential medium
(a-MEM). Transient transfection of expression constructs by Lipo-
fectamineTM (Invitrogen) was performed as previously described
[8]. For the use of N-glycosylation inhibitors, cells were incubated
with the following inhibitors: tunicamycin at 0.1 lg/ml, 1 lg/ml
and 10 lg/ml, castenospermine (CAS) at 50 lg/ml, 1-deoxynojiri-
mycin (DNJ) at 100 mM, swainsonine (SW) at 10 lg/ml. In all cases,
cells were pre-treated with the inhibitors for 12 h, replaced with
fresh OPTI-MEM I medium containing inhibitors for a further 24 h.
2.2. Construction of expression vectors
All expression vectors were constructed using pcDNA3.1(+) or
pcDNA3.1/myc-His vectors (Invitrogen) unless otherwise speciﬁed.
EMR2- and CD97-mFc expression constructs have been described
previously [8,25]. The chimeric and N-glycosylation site mutants
were generated using polymerase chain reaction (PCR) ampliﬁca-
tion by Advantage HF 2 PCR Kit (BD) using site-speciﬁc mutant
primers (Supplementary Table S1).
2.3. Production, puriﬁcation and glycosidase treatment of mFc-fusion
proteins
The production and puriﬁcation of mFc-fusion proteins were
carried out as described previously [8]. Puriﬁed proteins were dia-lyzed in 50 mM Tris–HCl, pH 7.4, buffer containing 10 mM CaCl2
and 150 mM NaCl at 4 C. The puriﬁed proteins were subjected
to glycosidase treatment by incubation with 1 U of PNGase F, 1 U
of Neuraminidase (Roche Applied Science) in 20 mM sodium phos-
phate buffer, pH 7.0, at 37 C for 20 h prior to SDS–PAGE analysis.
2.4. Western blotting and other protein analysis
For Western blotting, proteins were separated in 8% or 10%
SDS–PAGE gels, blotted and probed with anti-mFc or CLB/CD97-1
mAbs. For the in vitro cleavage of mFc-fusion proteins, afﬁnity-
puriﬁed CD97-mFc, EMR2(125)-H516S-mFc, or EMR2(125)-
S518A-mFc-fusion proteins were incubated in cleavage buffer
(50 mM Tris, pH 7.5, 50 mM NaCl, 1 mM EDTA) with or without
250 mM NH2OH (HA) at 37 C. At various time points, samples
were withdrawn and analyzed by Western blotting. For the quan-
titative analysis of protein bands, the intensity of the uncleaved
and cleaved protein bands on Western blots was quantiﬁed using
Gel-Pro Analyzer 3.1 (Media Cybernetics, MD, USA) according to
the manufacturer’s instructions.3. Results
3.1. Detection of different GPS auto-proteolytic activities in CD97 and
EMR2
While investigating the GPS cleavage of EMR2-mFc in previous
experiments, CD97-mFc was included for comparison. Surpris-
ingly, we detected very different degree of cleavage (DOC) in the
two molecules; EMR2-mFc is almost entirely cleaved (>95% DOC)
as reported, but the cleavage of CD97-mFc is only partial (50%
DOC) (Fig. 1A). The same results were observed in all cell lines
tested including CHO-K1, COS-7 and HEK-293T (data not shown).
Most importantly, similar results were seen in the membrane form
of CD97, indicating that the cleavage of CD97-mFc mimics that of
CD97 receptor (Supplementary Fig. S1). A point mutation at the
GPS site (CD97-S531A) completely inhibits the cleavage, suggest-
ing the cleavage mechanism of CD97 is highly similar, if not iden-
tical, to that of EMR2 (Supplementary Fig. S1). To further conﬁrm
the partial cleavage of CD97-mFc, fusion proteins were afﬁnity
puriﬁed and analyzed by SDS–PAGE. As shown in Fig. 1B, two
broad bands of 95–125 kDa and 50–75 kDa were identiﬁed,
representing the unprocessed molecule and the cleaved extracellu-
lar subunit, respectively. A third distinct band of 35 kDa is that of
cleaved mFc fragment. Subsequent de-glycosylation reaction con-
ﬁrmed the two broad bands are indeed due to heavy glycosylation
as reported (Fig. 1B and Supplementary Fig. S2) [26].
We have previously shown that strong nucleophiles such as
hydroxylamine (HA) can greatly enhance the processing rate of
an incomplete GPS proteolytic reaction [8]. This is achieved by
facilitating the hydrolysis of the (thio)ester intermediate, the
rate-limiting step of the GPS proteolytic reaction. To investigate
whether the uncleaved CD97-mFc identiﬁed here is the result of
an incomplete proteolytic reaction (i.e. a stalled intermediate) or
a truly unprocessed product, puriﬁed proteins were treated with
HA in an in vitro cleavage reaction (Fig. 1C). As expected, enhanced
cleavage was observed in a ‘‘cleavage-incomplete” protein, EMR2
H516S-mFc, in the presence of HA. On the contrary, no cleavage
was detected in cleavage-deﬁcient EMR2 S518A-mFc. Similar to
the cleavage-deﬁcient EMR2 molecule, CD97-mFc showed no en-
hanced proteolysis upon HA treatment. This indicated that the
uncleaved CD97-mFc is a cleavage-incompetent molecule
(Fig. 1C). Altogether, these results suggest that CD97-mFc can
adopt two different conformations; one capable of auto-proteolysis
and the other not.
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Fig. 1. Detection of different GPS auto-proteolytic activities in CD97 and EMR2. (A) The EGF-like modules and the stalk region are represented by triangles and a black line,
respectively. The GPS cleavage site is indicated by an arrow. Western blot analysis of the CD97-mFc (lane 4) and EMR2-mFc (lane 3) is shown. Lanes 1 and 2 are mock and
mFc-only control, respectively. Blots were probed with HRP-conjugated anti-mouse Fc-speciﬁc mAb that detects the uncleaved protein (100 kDa) and the mFc subunit
(36 kDa). (B) Afﬁnity puriﬁed CD97-mFc proteins were digested without (lane 1) or with PNGase and neuraminidase (lane 2) and visualized by Coomassie brilliant blue
staining. M represents the protein marker (in kDa). The uncleaved protein, the cleaved ECD and mFc subunits are represented by black arrowhead, white arrowhead and
asterisk, respectively. (C) Western blot analysis of CD97-mFc and mutant EMR2-mFc-fusion proteins subjected to in vitro cleavage reaction in the presence of NH2OH (HA) at




Fig. 2. GPS auto-proteolysis is mainly regulated by the stalk region. (A) Diagrams depict the EMR2-mFc, CD97-mFc and domain-swapping fusion proteins (indicated by
numbers 1–6, respectively). Western blot analysis of these fusion proteins is shown in the right panel. (B) Sequence alignments of the GPS motifs that are known to be
cleaved. The conserved residues are highlighted in grey background. The arrow and the boxes indicate the cleavage site and the potential N-glycosylation sites, respectively.
The abbreviations represent animal species (h, human; m, mouse; r, rat; d, Drosophila). (C) Western blot analysis of cleavage of the mFc-fusion proteins. Samples include
mock-transfected cells (lane 1), cells transfected with constructs expressing mFc (lane 2), EMR2-mFc (lane 3), CD97-mFc (lane 4), EMR3-mFc (lane 5) and EMR4-mFc (lane 6)
proteins.
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stalk region
To locate the region involved in the regulation of GPS auto-
proteolysis, we established and compared domain-swapping
chimeras of EMR2-mFc and CD97-mFc because of their strong sim-
ilarity (Fig. 2). As expected, Fig. 2A shows the auto-proteolytic
activity is mainly determined by the less homologous stalk region(also see Supplementary Fig. S3A). A closer examination of the stalk
region of related adhesion-GPCRs identiﬁed an interesting pattern
of potential N-glycosylation sites. A minimum of one N-glycosyla-
tion site is present in the GPS motif of all adhesion-GPCRs sur-
veyed, except EMR2 (Fig. 2B). Furthermore, 50% and 75% DOC
was identiﬁed in EMR3 and EMR4, two EGF-TM7 members that
contain two and one N-glycosylation sites in the GPS motif, respec-
tively (Fig. 2C and Supplementary Fig. S3B) [27,28]. These results
3288 C.-C. Hsiao et al. / FEBS Letters 583 (2009) 3285–3290suggest that N-glycosylation in the stalk region (and the GPS
domain) might play a role in determining the conformation of
EGF-TM7-mFc-fusion proteins and hence the DOC.
3.3. Regulation of GPS proteolysis in CD97-mFc by N-glycosylation
N-Linked glycans play an essential role in ER quality control as a
vital determinant for the proper folding of proteins. To examine the
role of N-glycosylation in regulating GPS cleavage, CD97-mFc and
EMR2-mFc transfected cells were treated with various N-glycosyl-
ation inhibitors (Fig. 3A and B). Tunicamycin interferes with the
ﬁrst step of glycoprotein synthesis by inhibiting the enzymatic
reaction catalyzing the transfer of core oligosaccharides to the nas-
cent peptide chain. Because N-glycosylation inﬂuenced protein
secretion, we could not detect CD97-mFc and EMR2-mFc proteins
in the conditioned media of tunicamycin-treated cells. However,
we noticed the DOC of newly synthesized proteins within the
tunicamycin-treated cells was greatly reduced (Fig. 3A). The reduc-
tion is observed for both CD97-mFc and EMR2-mFc, but is more
prominent in CD97-mFc, rendering it almost entirely uncleaved.
Unlike the tunicamycin treatment however, no signiﬁcant effect
on the DOC of CD97-mFc and EMR2-mFc was observed in cells
treated with castanospermine (CAS) and 1-deoxynojirimycin
(DNJ), both glucosidases I and II inhibitors (Fig. 3B). The same is
true for cells treated with swainsonine (SW), a Golgi alpha-man-
nosidase II inhibitor. Likewise, when analyzed in Lec1 cells, which
lacks N-acetylglucosaminyltransferase I activity, the DOC of both
EMR2-mFc and CD97-mFc was not altered (Fig. 3C). These results
are consistent with the consensus that proteolysis takes place
within ER. Our data further indicate that GPS cleavage occurs after
the attachment of the oligosaccharide precursor, but does not de-
pend on its subsequent processing.Fig. 3. Regulation of GPS proteolysis of CD97-mFc molecule by N-glycosylation. (A) Wes
EMR2-mFc proteins. (B) Western blot analysis of the effect of various N-glycosylation inh
The expression patterns of CD97-mFc (lane 2) and EMR2-mFc (lane 1) in Lec 1 cells.3.4. The role of site-speciﬁc N-glycosylation in the regulation of GPS
proteolysis in CD97-mFc
A total of 5 potential N-glycosylation (G) sites were identiﬁed in
the stalk regions of CD97 (Fig. 4A). To investigate the role of site-
speciﬁc N-glycosylation in GPS auto-proteolysis, we created and
evaluated the DOC of single and multi-N-glycosylation site mu-
tants of CD97-mFc proteins. In comparison to the wild-type (WT)
protein, all single N-glycosylation site mutants showed slight ef-
fects on the DOC either positively or negatively (Fig. 4B and Sup-
plementary Fig. S4A). To show this effect is speciﬁc and not
simply due to residue changes, we established single mutants
replacing the three individual residues of the ﬁrst N-glycosylation
site (G1) (N371Q, V372A and T373A). The DOC of V372A mutant,
which should preserve N-glycosylation, was similar to the WT pro-
tein. On the other hand, both N371Q and T373A mutants all
showed similar enhanced DOC (Fig. 4B).
Intriguingly, signiﬁcant modulation of GPS proteolysis was ob-
served in multi-N glycosylation site mutants. The cleavage of
CD97(G2,3), CD97(G1-3), CD97(G2-4), CD97(G2-5), and CD97(G1-
5) mutants was greatly reduced (only 1–10% DOC), whereas the
processing of CD97(G4,5) and CD97 (G1,4,5) mutants was efﬁ-
ciently enhanced with the DOC of CD97(G4,5) reaching 95%
(Fig. 4B and Supplementary Fig. S4B). These results indicate that
site-speciﬁc N-glycosylation in the stalk region is critically in-
volved in the GPS auto-proteolysis of CD97-mFc. Speciﬁcally, com-
bined mutation at the 2nd and 3rd glycosylation sites, G2(N406) and
G3(N413), seem to reduce GPS auto-proteolysis. Conversely, muta-
tion involving the 4th and 5th sites (G4,5) greatly enhances prote-
olysis. Interestingly, the effect of G2,3 mutations on the DOC seems
to dominate over that of G4,5 mutations, as exempliﬁed by the
mostly uncleaved CD97(G2-5) and CD97(G1-5) mutants (Fig. 4B).tern blot analysis of the effect of tunicamycin on the GPS cleavage of CD97-mFc and
ibitors (CAS, DNJ, SW) on the GPS cleavage of CD97-mFc and EMR2-mFc proteins. (C)
A B
Fig. 4. Regulation of GPS proteolysis of CD97-mFc molecule by site-speciﬁc N-glycosylation. (A) Diagram depicting the wild-type (WT) CD97-mFc molecule, with a special
attention on the potential N-glycosylation sites. The 5N-glycosylation sites in the stalk were denoted as G1, G2, G3, G4, and G5, respectively. (B) Western blot analysis of
various CD97-mFc proteins including the WT and N-glycosylation site mutants.
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As evidenced by genetic diseases caused by mutations that af-
fect GPS cleavage, the self-catalytic proteolysis at the GPS domain
is no doubt an essential post-translational modiﬁcation of the GPS
domain-containing receptors. However, several recent studies
have reported the detection of both cleaved and uncleaved adhe-
sion-GPCRs, including GPR56 and ﬂamingo, in vivo [29,30]. These
results strongly suggest that the GPS auto-proteolytic reaction is
regulated and that the cleaved and uncleaved adhesion-GPCRs
could potentially have different cellular functions. This is consis-
tent with the recent ﬁnding by Yu et al. on the functions of polycy-
stin-1, a GPS motif-containing 11-TM molecule associated with
ADPKD [31]. By comparing the phenotypes of the Pkd1 null and a
speciﬁc Pkd1 knock-in animal model expressing only the noncleav-
able polycystin-1, Yu and colleagues demonstrated that the
cleaved polycystin-1 is critical for kidney tubular integrity, while
the uncleaved polycystin-1 is required for embryonic development
[31]. The fact that both cleaved and uncleaved polycystin-1 mole-
cules have distinct biological functions is also reﬂected by the
expression of the respective protein products in vivo [31,32].
These observations indicated that although the GPS proteolysis
is self-catalytic, the reaction is probably not 100% efﬁcient. Alter-
natively, it is possible that the adhesion-GPCRs can adopt different
conformations and proceed with or without GPS cleavage. Our data
on the regulation of GPS cleavage in CD97 seem to support the lat-
ter mechanism. Likewise, a similar conclusion was reached by Wei
et al. who demonstrated that endogenous polycystin-1 can mature
via two different pathways leading to the production of uncleaved
full-length molecule as well as cleaved products [32]. The degree of
cleavage (DOC) shown in this report was determined by comparing
the ratio of the uncleaved to cleaved protein bands on Western
blots. This was based upon the assumption that all mutant proteins
have similar protein stability. As N-glycans are important for pro-
tein stability, it should be cautioned that it is also likely that the re-
moval of N-glycans at certain positions can inﬂuence the overall
protein stability and turn-over. This effect, if occurred, will affect
the measurement of DOC, even though it might not really affect
GPS cleavage. Detailed structural analysis of these individual pro-
teins by other means such as the circular dichroism spectroscopy
or conformational unfolding studies in the future should help dis-
tinguish these potential effects.
Based upon available experimental evidence, we suggest a
model where the folding of adhesion-GPCRs in ER can lead to
either a cleavable or uncleavable conformation. In CD97-mFc, the
structural determinant for the two distinct conformations was
found to include site-speciﬁc N-glycosylation in the stalk region(Figs. 2–4). Consistent with the consensus that GPS cleavage takes
place in the ER lumen, we hypothesize that N-glycosylation at spe-
ciﬁc sites of CD97 stalk promotes the folding of CD97-mFc precur-
sor to a favorable conformation to allow GPS cleavage reaction. If
the favorable condition is not met due to differential N-glycosyla-
tion, the precursor molecule will adopt a different conformation
that is cleavage-incompetent and thus is expressed as an unc-
leaved single-chain protein.
Because of the heterogenous nature of the N-glycosylation site
occupancy [33], it is possible to produce receptors containing var-
iable degrees of N-glycosylation leading to cleavable and uncleav-
able conformations. This implies a regulatory mechanism whereby
the eventual cellular function of a speciﬁc adhesion-GPCR could
possibly be determined by the efﬁciency of site-speciﬁc N-glyco-
sylation, and hence the relative amounts of the cleaved and unc-
leaved receptors. From this point of view, it is interesting to note
that all GPS domain-containing receptors, including adhesion-
GPCRs and polycystin-1, contain an extracellular stalk rich in po-
tential N- and O-glycosylation sites that are in close proximity of
the GPS motif. It will be interesting in the future to analyze
whether different factors other than N-glycosylation are involved
in the regulation of GPS auto-proteolytic reaction. Such informa-
tion should in turn help shed lights on the generation and the bio-
logical functions of the cleaved and uncleaved adhesion-GPCRs.
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